KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Employing skin self-examination and fear of cancer recurrence management in early-stage melanoma follow-up: evaluation of the MELACARE intervention in a randomised controlled trial. PMID 40504479 · J Cancer Surviv · 2025-Jun-12 The study is an oncology, human, randomized controlled trial with original results, but it is excluded because it evaluates a non-drug intervention (nurse-led follow-up program) and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. PMID 40504283 · J Neurol · 2025-Jun-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. PMID 40421736 · N Engl J Med · 2025-Jun-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Nerandomilast in Patients with Progressive Pulmonary Fibrosis. PMID 40388329 · N Engl J Med · 2025-Jun-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. PMID 40387033 · N Engl J Med · 2025-Jun-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. PMID 40090011 · Blood · 2025-Jun-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial. PMID 40558655 · J Cardiovasc Dev Dis · 2025-Jun-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. PMID 40500695 · Mol Cancer · 2025-Jun-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Home-based online exercise training and chronic, low-grade inflammation in cancer patients after curative surgery: secondary analysis of the randomized controlled multicenter CRBP-TS trial. PMID 40498221 · Support Care Cancer · 2025-Jun-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Lung cancer screening in Finland: a prospective randomized trial. PMID 40497290 · Acta Oncol · 2025-Jun-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Non-randomised prospective clinical trial to improve follow-up adherence, survivorship knowledge and late effects documentation at a childhood cancer clinic in Western Kenya: a study protocol. PMID 40499965 · BMJ Open · 2025-Jun-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical effect of ePRO-based symptom monitoring and management on improving survival outcomes in patients with advanced cancer: a single-centre, prospective, randomised controlled trial protocol. PMID 40499961 · BMJ Open · 2025-Jun-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone as the first line treatment for advanced biliary tract cancer: a pooled analysis of KEYNOTE-966 and TOPAZ-1 trails. PMID 40495210 · World J Surg Oncol · 2025-Jun-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The effect of supportive care on mood, general health, competence on caregivers of cancer patients, and supportive care needs on cancer patients undergoing chemotherapy: a controlled clinical trial. PMID 40493212 · Support Care Cancer · 2025-Jun-10 The study is a randomized controlled trial in oncology (cancer patients undergoing chemotherapy). However, the intervention is a 'supportive care program' (psychosocial/nursing), not a drug-containing intervention (the chemotherapy is routine, not the intervention under study). The endpoints are quality-of-life, caregiver burden, and supportive care needs (PROs), not time-to-event efficacy endpoints (OS, PFS, etc.). It is also not a Phase III/IIIb or Phase II/III trial (no phase specified).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation. PMID 40388602 · J Gerontol A Biol Sci Med Sci · 2025-Jun-10 The record describes an observational cohort study (target trial emulation) comparing metformin versus sulfonylureas for longevity in women with type 2 diabetes. It is not an oncology study, not a randomized trial, and not a Phase III or Phase II/III randomized trial with a drug intervention for a malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Sodium Oxybate in Adults With Idiopathic Hypersomnia: A Randomized Controlled Trial. PMID 40359459 · Neurology · 2025-Jun-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial. PMID 40332892 · JAMA · 2025-Jun-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. PMID 40294366 · J Clin Oncol · 2025-Jun-10 The record describes a cross-study analysis comparing outcomes of hematopoietic stem cell transplantation (HSCT) versus chemotherapy alone in pediatric high-risk AML patients. While it references Phase III trials and reports DFS (time-to-event), it does not meet all inclusion criteria. Specifically, it is not a primary report of a single randomized trial; it is a secondary analysis combining data from two trials. More critically, the intervention of interest is HSCT (a procedure), not a drug-containing intervention. The comparison involves chemotherapy, but the focus is on the transplant procedure. The randomization status for the specific comparison in this analysis is also not explicitly established in the abstract.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial. PMID 40249893 · J Clin Oncol · 2025-Jun-10 The study is a randomized Phase III trial in oncology with a drug intervention (concurrent chemotherapy) and reports an original result. However, it does not meet the primary requirement of having a time-to-event efficacy endpoint (like OS or PFS) as the primary or key secondary outcome. The abstract explicitly reports only early toxicity within 6 months, which is a safety endpoint, not an efficacy endpoint with time-to-event characteristics (e.g., Kaplan-Meier, HR). Therefore, it is excluded.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study). PMID 40184561 · J Clin Oncol · 2025-Jun-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. PMID 40156843 · Circulation · 2025-Jun-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Inter-cluster contamination: a semivariance analysis of community effect ranges of malaria vector control interventions in a four-armed malaria trial in Muleba, Tanzania. PMID 40490768 · Malar J · 2025-Jun-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial. PMID 40483523 · Arthritis Res Ther · 2025-Jun-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. PMID 40460847 · Lancet · 2025-Jun-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intraoperatively preventive intraperitoneal perfusion chemotherapy with lobaplatin in colorectal cancer: a prospective, randomised, controlled, multicentre study. PMID 40481437 · BMC Med · 2025-Jun-06 The record describes an oncology randomized trial with a drug intervention and time-to-event endpoints. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, or publication types). The 'deterministic_review' signal 'phase3: false' indicates this criterion cannot be confirmed. Without explicit phase information, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Study protocol for the Outcomes Post-Treatment: Impact on Motor Impairment of Sleep Efficiency in Spinal Cord Injury (OPTIMISE SCI) - a randomised controlled trial. PMID 40480676 · BMJ Open · 2025-Jun-06 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effects of a remote therapeutic education programme involving peers and health professionals on physical activity in patients with coronary heart disease undergoing phase 3 cardiac rehabilitation: protocol for a single-centre randomised controlled trial. PMID 40480674 · BMJ Open · 2025-Jun-06 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Enhancing postoperative recovery in robotic-assisted prostatectomy: a randomized trial of LEARNS model, auricular acupressure, and intestinal rehabilitation. PMID 40471457 · J Robot Surg · 2025-Jun-05 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis. PMID 40468999 · Acta Oncol · 2025-Jun-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. PMID 40305708 · N Engl J Med · 2025-Jun-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Local therapy for oligometastatic prostate cancer. PMID 40088427 · Jpn J Clin Oncol · 2025-Jun-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113. PMID 40052520 · Jpn J Clin Oncol · 2025-Jun-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study). PMID 39997358 · Jpn J Clin Oncol · 2025-Jun-05 The record describes a Phase III randomized trial protocol for a maintenance study in follicular lymphoma, but the abstract does not report any time-to-event efficacy results. It is a protocol/registration summary without primary or secondary outcome data.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study. PMID 40542585 · Oncologist · 2025-Jun-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy. PMID 40488582 · J Crohns Colitis · 2025-Jun-04 The record describes a non-oncology disease (ulcerative colitis) and does not report a primary/key secondary time-to-event efficacy endpoint for human malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of 15- or 25-min intermittent Pringle maneuver on early recurrence of hepatocellular carcinoma after hepatectomy: a protocol for a randomized controlled trial. PMID 40468382 · Trials · 2025-Jun-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A randomized controlled trial exploring the effect of placement versus nonplacement of a drainage tube around the cervical anastomosis in McKeown esophagectomy. PMID 40467612 · Sci Rep · 2025-Jun-04 The trial is a surgical RCT without a drug intervention and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant chemotherapy or chemoradiotherapy plus sintilimab versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a study protocol of a multicentre, randomised, controlled, phase III trial (SCIENCE study). PMID 40467307 · BMJ Open · 2025-Jun-04 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). PMID 40243842 · J Crohns Colitis · 2025-Jun-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies. PMID 40461265 · RMD Open · 2025-Jun-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Consensus process to agree upon surgical quality assurance processes within a pragmatic, multicentre randomised clinical trial comparing targeted axillary dissection and axillary node clearance: the TADPOLE-TOGETHER project. PMID 40461151 · BMJ Open · 2025-Jun-03 The record is a protocol for a surgical randomized controlled trial in oncology (breast cancer), but it does not report results of a drug-containing intervention with a time-to-event efficacy endpoint. The intervention is surgical, and the publication is a protocol describing a quality assurance process, not an original result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Midurethral Sling vs OnabotulinumtoxinA in Females With Urinary Incontinence: The MUSA Randomized Clinical Trial. PMID 40323617 · JAMA · 2025-Jun-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study): A phase III crossover trial. PMID 40311506 · Eur J Cancer · 2025-Jun-03 The study is a phase III, randomized, oncology, human, drug-intervention trial with original results. However, it is ineligible because the prespecified efficacy endpoints are response rates (categorical outcomes), not time-to-event outcomes as required by the cohort definition.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. PMID 40306121 · Eur J Cancer · 2025-Jun-03 The record describes a pooled analysis of two prior Phase III trials, evaluating a prognostic factor (relative dose intensity). It is not the primary or secondary result report of a single randomized trial. The intervention (FOLFOXIRI vs. doublets) was randomized in the parent trials, but this analysis is a post-hoc/prognostic subgroup analysis, not the original trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial. PMID 40279684 · Eur J Cancer · 2025-Jun-03 The record describes a randomized, drug-intervention trial in advanced melanoma reporting time-to-event efficacy outcomes (PFS, OS), but the provided metadata does not explicitly confirm it as a Phase III/IIIb or Phase II/III trial. The deterministic review flagged phase evidence as unclear. Without explicit phase confirmation, eligibility cannot be established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Randomized Control Trial of Two Interventions Compared with Usual Care for Increasing Cervical Cancer Screening among Women Living in the Rural Midwest. PMID 40197927 · Cancer Epidemiol Biomarkers Prev · 2025-Jun-03 The study is an oncology-related randomized trial, but it does not meet the key eligibility criteria: it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) and does not involve a drug-containing intervention (comparing a DVD/patient navigation intervention vs. usual care).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study. PMID 40100121 · Clin Cancer Res · 2025-Jun-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Probability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis. PMID 39861972 · J Bone Miner Res · 2025-Jun-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia. PMID 40549387 · JAMA Netw Open · 2025-Jun-02 The record describes a pharmacogenomic cohort study analyzing outcomes from a randomized trial (AAML1031) and other protocols. While it contains elements of a randomized trial (AAML1031) with drug intervention and time-to-event endpoints, the abstract does not explicitly state the phase of the AAML1031 trial (Phase II, III, etc.), and the primary analysis is a retrospective pharmacogenomic validation study across multiple cohorts, not a primary report of the definitive randomized trial efficacy results. Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Interaction effect of comorbid depression and proactive positivity coping strategy on the 1-year survival of patients with advanced cancer: a nationwide multicentre study in South Korea. PMID 40457290 · BMC Psychiatry · 2025-Jun-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -